Braf mutation-positive tumors
Drug research and approvals for braf mutation-positive tumors: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 10 studies of braf mutation-positive tumors are recruiting on ClinicalTrials.gov, and Health Canada has authorized 5 drug trials for it since 2013.
- Recruiting worldwide: 10
- Trials authorized in Canada: 5
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 10 recruiting on ClinicalTrials.gov ↗- A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in…NCT07789210 · Phase 2 · Zhejiang University · starts Jun 30, 2026
- DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young…NCT07440290 · Phase 2 / Phase 3 · Cancer Research UK · starts Apr 1, 2026
- Special Drug Use-results Surveillance of Tafinlar/MekinistNCT06262919 · Not reported · Novartis Pharmaceuticals · starts Feb 9, 2024
- Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E…NCT05868629 · Not reported · Novartis Pharmaceuticals · starts Feb 6, 2024
- A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal CancerNCT05639413 · Not applicable · UNICANCER · starts Jul 24, 2023
- Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesNCT05786924 · Phase 1 / Phase 2 · Institut de Recherches Internationales Servier · starts Apr 18, 2023
- DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive…NCT05768178 · Phase 2 / Phase 3 · Cancer Research UK · starts Mar 1, 2023
- Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum…NCT05706779 · Phase 2 · Federation Francophone de Cancerologie Digestive · starts Feb 13, 2023
- Clinical Study of Neoadjuvant Targeted Therapy for AmeloblastomaNCT06653517 · Phase 2 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · starts Jan 1, 2023
- A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsNCT04913285 · Phase 1 · Pierre Fabre Medicament · starts Aug 4, 2021
Trials Authorized in Canada
Newest first; search them all in Canada trials| Jul 3, 2019 | An open label, multi-center roll-over study to assess long-term effect in pediatric patients treated with tafinlar (dabrafenib) and/or mekinist (trametinib)DABRAFENIB (DRB436)/ TRAMETINIB (TMT212) | Novartis Pharmaceuticals Corporation | Ongoing |
| Mar 18, 2016 | Phase II open-label global study to evaluate the effect of dabrafenib treatment in children and adolescent patients with braf v600 mutation positive relapsed…TAFINLAR (DABRAFENIB, DRB436)/ TRAMETINIB | Novartis Pharmaceuticals Corporation | Closed |
| Jun 23, 2014 | An open-label, dose-escalation, phase I/ii study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of the mek inhibitor…TRAMETINIB (GSK1120212) / DABRAFENIB (GSK2118436) | Novartis Pharmaceuticals Corporation | Closed |
| Nov 15, 2013 | A phase II, open-label, study in subjects with braf v600e-mutated rare cancers with several histologies to investigate the clinical efficacy and safety of the…DABRAFENIB (GSK2118436)/ TRAMETINIB (GSK1120212) | Novartis Pharmaceuticals Corporation | Closed |
| Oct 23, 2013 | A phase 1 and pharmacokinetic study of dabrafenib (gsk2118436b) in patients with brafv600x mutations and renal or hepatic dysfunction.DABRAFENIB | PRINCESS MARGARET HOSPITAL PHASE I CONSORTIUM | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA